Voyager Therapeutics (VYGR) said Monday the joint steering committee with collaborator Neurocrine Biosciences (NBIX) selected a third development candidate in a gene therapy program to potentially treat an undisclosed neurological disease.
The move triggered a $3 million milestone payment to Voyager, expected to be received in Q4, the company said.
Voyager said it is eligible to receive additional development and commercialization milestone payments in the future, subject to further advancement of the program.
Price: 6.18, Change: -0.08, Percent Change: -1.20
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments